Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Technology Combines Speed of Rapid Antigen Test with Accuracy of PCR Testing to Detect COVID-19 in 4 Minutes

By LabMedica International staff writers
Posted on 10 Feb 2022

Scientists have developed a new coronavirus test that is accurate as a polymerase chain reaction (PCR) lab test but gives results within four minutes. More...

The test developed by researchers at Fudan University (Shanghai, China) uses a hypersensitive electromechanical biosensor to detect nucleic acids that were earlier difficult to identify owing to their low concentration in test samples. The sensor which uses microelectronics to analyze genetic material from swabs could reduce the need for time-consuming lab tests for diagnosing COVID-19.

PCR tests are the most accurate and sensitive for detecting SARS-COV-2, the virus that causes COVID-19, although they can take several hours to deliver results. Rapid antigen tests are a quicker alternative and deliver results in 15 minutes but are less reliable than PCR tests which are more accurate due to their greater sensitivity. In comparison to PCR tests, antigen tests require a higher concentration of the virus to exhibit a positive result due to which they are more likely to show a false negative. Antigen tests look for pieces of virus-infected proteins, while PCR tests search for viral genetic material such as nucleic acids and RNA.

Currently, there is no technology that can properly detect COVID-infected nucleic acids and RNA without using extraction and amplification methods which require a lab environment. The new method that uses a hypersensitive electromechanical biosensor to detect nucleic acids offers speed, ease of operation, high sensitivity and portability. Portable tests based on this technology could be used for on-site COVID-19 testing at airports, clinics, emergency departments and at home, as well as for quickly diagnosing other types of diseases.

In a clinical trial of the new test, the researchers collected nasal samples from 33 PCR-positive COVID-19 patients, 23 PCR-negative patients, six influenza-positive patients and 25 healthy volunteers. The researchers found that the test accurately processed all the cases without any errors in less than four minutes. The trial was conducted on a small sample, and if the 100% accuracy rate was replicated in a larger test sample, then the new test could be a game changer in COVID-19 diagnosis.

"We implemented an electromechanical biosensor for the detection of SARS-CoV-2 into an integrated and portable prototype device, and show that it detected (virus RNA) in less than four minutes," the team said in a peer-reviewed article describing their molecular electromechanical system, or MolEMS, in the journal Nature Biomedical Engineering.

Related Links:
Fudan University 


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Flock Tipped Applicator
HydraFlock 6" Sterile Large Flock Swab w/Polystyrene Handle, 80mm Breakpoint
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.